extended interval dosing for pembrolizumab - lung cancer onctalk 2022
Published 1 year ago • 49 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
2:00
keynote 671: perioperative pembrolizumab for nsclc - onctalk lung 2023
-
2:02
progression on pembrolizumab: patient without actionable mutations & low pd-l1 - lung cancer onctalk
-
1:48
preoperative or postoperative immunotherapy? - lung cancer onctalk 2022
-
1:57
keynote 091: adjuvant pembrolizumab - onctalk lung 2023
-
4:56
dual immune checkpoint blockade with or without chemotherapy - lung cancer onctalk 2022
-
2:11
treating side effects from neoadjuvant chemoimmunotherapy - lung cancer onctalk 2022
-
2:52
preoperative versus postoperative treatment - lung cancer onctalk 2022
-
2:12
neoadjuvant, perioperative, adjuvant: defining terms and advantages - onctalk lung 2023
-
6:00
immunotherapy for patients with driver mutation - lung cancer video library
-
2:40
krystal 7 study: adagrasib /- pembrolizumab for kras g12c nsclc -targeted therapies in lung cancer
-
6:52
combination chemotherapy and immunotherapy for patients with high pd-l1 nsclc - 2022 program: lcvl
-
3:40
platinum-based chemo doublets: backbone for nsclc treatment
-
4:15
treatment timing for multiple myeloma - blood cancer onctalk
-
5:09
immunotherapy for lung cancer: general concepts
-
2:58
grace targeted therapies lung cancer 2021 - is there a benefit of having higher dose osimertinib?
-
2:44
approaching treatment for smoldering multiple myeloma - blood cancer onctalk 2023
-
2:22
neotorch trial: perioperative toripalimab for nsclc - onctalk lung 2023